Health
Obesity Drugmaker BioAge Seeks $158 Million in IPO, Placement
- Company selling 7.5 million shares for $17 to $19 each
- Backers include Andreessen Horowitz and Khosla Ventures
BioAge Labs Inc., a clinical-stage biotechnology company developing therapies for obesity and metabolic disease, is seeking to raise as much as $157.5 million in its initial public offering and a private placement.
The company is offering 7.5 million shares for $17 to $19 apiece, according to a filing Wednesday with the US Securities and Exchange Commission. Separately, Sofinnova Venture Partners XI LP, an existing shareholder, is expected to purchase about $15 million worth of shares at the IPO price in a private placement.